Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.38 - $0.65 $171 - $293
451 Added 33.88%
1,782 $0
Q2 2023

Feb 14, 2024

SELL
$0.23 - $0.39 $103 - $175
-451 Reduced 25.31%
1,331 $0
Q1 2023

May 11, 2023

SELL
$0.3 - $0.56 $800 - $1,494
-2,669 Reduced 66.73%
1,331 $1,000
Q4 2022

Feb 07, 2023

BUY
$0.26 - $0.64 $650 - $1,600
2,500 Added 166.67%
4,000 $1,000
Q3 2022

Nov 09, 2022

SELL
$0.48 - $1.11 $1,940 - $4,486
-4,042 Reduced 72.93%
1,500 $1,000
Q2 2022

Aug 11, 2022

SELL
$0.41 - $0.88 $615 - $1,320
-1,500 Reduced 21.3%
5,542 $3,000
Q1 2022

May 09, 2022

BUY
$0.74 - $1.22 $5,180 - $8,540
7,000 Added 16666.67%
7,042 $6,000
Q3 2021

Nov 08, 2021

BUY
$1.83 - $3.18 $76 - $133
42 New
42 $0

Others Institutions Holding CYBN

About CYBIN INC.


  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $1.58B
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track This Portfolio

Track Toronto Dominion Bank Portfolio

Follow Toronto Dominion Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

News

Stay updated on Toronto Dominion Bank with notifications on news.